News

Implementing nationwide screening programs for Fabry disease in people with a heart condition called hypertrophic cardiomyopathy (HCM) may help improve diagnosis of the disease, a study in Czech Republic shows. In the country, the program led to the diagnosis of Fabry in four men and two women among the…

Mutations likely to cause Fabry disease, particularly those associated with late-onset disease, were found to be more common in an adult population of U.K. residents than the estimated prevalence of the disease itself, a genetic analysis showed. The findings suggest late-onset Fabry disease prevalence may be higher than…

Activating a mitochondrial protein called TRAP1 can help to improve the functionality of lysosomes, the cellular structures that are defective in Fabry disease, a new study reports. The study, “Activation of mitochondrial TRAP1 stimulates mitochondria-lysosome crosstalk and correction of lysosomal dysfunction,” was published in iScience.

AL01211, a once-daily oral therapy being developed by AceLink Therapeutics for Fabry disease, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to investigational treatments with the potential to improve care for rare diseases that affect fewer than…

Gene therapy ST-920 (isaralgagene civaparvovec) continues to be effective and well-tolerated in adults with Fabry disease, according to the latest data from an ongoing Phase 1/2 clinical trial that’s testing the experimental treatment. Five of the participants treated with ST-920 the longest — up to 15 months, or…

Doctors who treat Fabry disease tend to underappreciate the effect that symptoms like abnormal sweating and digestive complaints can have on a person’s quality of life, according to a new study conducted in Japan. The study also highlighted a disconnect in communication between doctors and patients when it comes…

Left ventricular hypertrophy (LVH) — a condition when the walls of the heart’s left pumping chamber (left ventricle) become thickened — accompanied by damages to peripheral nerves and hearing impairments could be signs of late-onset Fabry disease, according to a case report. “This case serves as a potent reminder…

A man with Fabry disease undergoing long-term dialysis to support kidney function and receiving enzyme replacement therapy (ERT) experienced recurrent complications related to blood vessels in his brain, a case study reported. While further investigation into such cases is needed, the researchers recommended that Fabry patients with end-stage…

The risk of severe COVID-19 in people with Fabry disease appears to be driven by immune system function rather than by the genetic disorder itself — “similar to the general population” — a small study concluded. “Immunosuppression therapy in kidney transplant recipients represented the highest risk in this [patient]…

The Fabry disease burden is variable but significant among adolescents and caregivers, affecting their quality of life and mental health, according to results of online surveys in three European countries. In addition, standard enzyme replacement therapy (ERT) was reported to reduce the disease’s burden, but not fully. These findings highlight…